![](https://geneva-network.com/wp-content/uploads/2018/10/eu-550x350.jpg)
The European Commission’s pharmaceutical innovation incentives review is at risk of serious overreach
The European Commission (EC) outlined its plans to introduce a manufacturing waiver for Supplementary Protection Certificates (SPCs). If adopted, it would open the door for generic manufacturers to export medicines outside the EU while the SPC is still in force.